China's Wingtech Technology is entering a critical phase marked by a sharp deterioration in financial performance, regulatory scrutiny, and operational disruption tied to its contested control of Nexperia. The convergence of these pressures is not merely a...
The article requires paid subscription.
Subscribe Now
